07:55 AM EDT, 10/01/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Tuesday that the US Food and Drug Administration has granted fast-track designation to zilganersen for the treatment of children and adults with a neurological disorder called Alexander disease.

The company said it expects topline data from its study of zilganersen in the second half of 2025, for which it completed enrollment in eight countries earlier this year.

Price: 39.21, Change: -0.85, Percent Change: -2.12